Capstone Wealth Management Group LLC Acquires 33 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Capstone Wealth Management Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,828 shares of the biopharmaceutical company’s stock after purchasing an additional 33 shares during the quarter. Regeneron Pharmaceuticals comprises about 1.3% of Capstone Wealth Management Group LLC’s investment portfolio, making the stock its 23rd largest position. Capstone Wealth Management Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,921,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Brown Lisle Cummings Inc. raised its position in shares of Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 10 shares in the last quarter. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Team Hewins LLC raised its position in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the period. Angeles Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 11 shares during the last quarter. Finally, TrinityPoint Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.8% in the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 12 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent research reports. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Argus upped their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Finally, Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,109.70.

Insider Activity

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,026 shares of company stock worth $11,498,705. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $1,153.08 on Tuesday. The company has a market capitalization of $127.05 billion, a price-to-earnings ratio of 34.06, a PEG ratio of 3.97 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The business’s fifty day simple moving average is $1,126.24 and its 200-day simple moving average is $1,027.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.79 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.